US cancer experts sounded a cautionary note Tuesday about a claim by a team of Israeli scientists that they will likely develop a cure for cancer in the next year.

The new treatment is being developed by Accelerated Evolution Biotechnologies under the leadership of CEO Dr. Ilan Morad, according to the Jerusalem Post.

“We believe we will offer in a year’s time a complete cure for cancer,” said Dan Aridor, chairman of the company’s board. “Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market.”

The scientists likened their treatment — called MuTaTo, for multi-target toxin — to a cancer antibiotic.

Morad equated the concept of MuTaTo to the drug cocktail that has helped transform AIDS from being an automatic death sentence to a chronic yet manageable disease, according to the Israeli news outlet.

The treatment uses a combination of cancer-targeting peptides — compounds of two or more amino acids linked in a chain — and a toxin that kills cancer cells.

By using at least three targeting peptides on the same structure with a strong toxin, Morad said, they “made sure that the treatment will not be affected by mutations; cancer cells can mutate in such a way that targeted receptors are dropped by the cancer.”

Patients would likely be able to stop treatment after several weeks and not need a drug cocktail throughout their lives, according to the scientists.

The treatment, which has not been tested in humans yet, has shown success in mice trials and is nearing the stage of clinical trial, Aridor said.

But Dr. Ben Neel, director of Perlmutter Cancer Center at NYU Langone Health, told The Post that “cancer is multiple diseases, and it is highly unlikely that this company has found a ‘cure’ for cancer any more than there is a single cure for infections.”

He said that “more likely, this claim is yet another in a long line of spurious, irresponsible and ultimately cruel false promises for cancer patients.”

Neel added in an email: “Of course, curing cancer is the goal of everyone who comes to work every day at a cancer center — and if this company does, in fact, cure cancer, they will have my congratulations and thanks.”

Dr. Len Lichtenfeld, chief medical officer of the American Cancer Society, said in a blog Tuesday that “it goes without saying, we all share the aspirational hope that they are correct. Unfortunately, we must be aware that this is far from proven as an effective treatment for people with cancer, let alone a cure.”

He said, “the key to the success of this research is apparently the focus of this experimental treatment approach on several abnormalities in cancer cells at the same time, limiting the ability of the cancer cell to change its genetic pattern and become resistant to typical treatments.”

Lichtenfeld noted that the Israeli team’s research has apparently not been published in the scientific literature, where it would be subject to peer review.

“If this group is just beginning clinical trials, they may well have some difficult experiments ahead,” he wrote.

“It is certainly possible this approach may be work. However, as experience has taught us so many times, the gap from a successful mouse experiment to effective, beneficial application of exciting laboratory concepts to helping cancer patients at the bedside is in fact a long and treacherous journey, filled with unforeseen and unanticipated obstacles.”